3D BioFibR Inc.

3D BioFibR Inc. , based in Canada, specializes in producing collagen fibers through patented dry-spinning technology, catering to the biomedical sector with advanced materials for tissue engineering. Founded in 2020 and headquartered in Halifax, Canada, 3D BioFibR Inc. focuses on developing and manufacturing collagen fibers for various applications in the life sciences industry.

The company has successfully completed 6 deals as of June 2025, raising a total of USD 3. 000 mn through recent funding rounds, including participation from investors such as Alliance of Angels, Build Ventures, Concrete Ventures, and Invest Nova Scotia. Kevin Sullivan serves as both the CEO and founder of the company, leading its innovative projects in biomedical research and regenerative medicine. 3D BioFibR specializes in the production of collagen fibers utilizing a patented dry-spinning technology that closely mimics the biomechanical and biochemical properties of natural collagen structures.

Their core offerings include collagen fibers designed for various tissue engineering applications, such as additives for 3D bioprinting, hydrogels, and cellular scaffolds suitable for both 2D and 3D cell and tissue culture. By leveraging a fully automated manufacturing system, they have achieved the ability to produce these fibers at commercial scales, catering to sectors such as biomedical research and regenerative medicine. The company serves a diverse client base, including research institutions, biotech firms, and pharmaceutical companies, primarily in North America, Europe, and select markets in Asia. Their products aim to address critical challenges in tissue engineering, enhancing the efficacy of cellular scaffolds and bioprinting technologies for a range of applications.

3D BioFibR's revenue model centers on direct transactions with businesses and institutions in the life sciences sector. Clients typically engage in B2B transactions, acquiring products through structured contracts that specify terms of supply for their collagen fibers and related products. The company’s flagship product, CollaFibR™, serves as a central offering, and clients may enter into agreements that include bulk purchasing arrangements or long-term partnerships for ongoing needs. Revenue generation occurs through these contracts, which may involve tiered pricing structures based on order volume and frequency.

The sales strategy emphasizes building strong relationships with key customers, ensuring that their innovative solutions meet specific applications in tissue engineering and regenerative medicine. In June 2025, 3D BioFibR Inc. raised USD 3. 000 mn in venture funding to enhance manufacturing capabilities, drive operational expansion, and achieve ISO 13485 certification.

The company plans to launch new products designed for advanced tissue engineering applications. Additionally, there are strategic plans to expand into European and Asian markets by 2026, utilizing recent funding to support these initiatives.